Alignment of Physician-Stated vs Clinically Derived Reference Fibrosis Score in Patients with Non-Alcoholic Steatohepatitis: A Real-World European Survey

References

• Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–344. doi:10.1038/nrgastro.2013.41
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. doi:10.1002/hep.29367
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Harrison S, Wilman H, Kelly M, et al. Prevalence and stratification of NAFLD/NASH in a UK and US cohort using non-invasive multiparametric MRI. J Hepatol. 2018;68(Suppl 1):S550. doi:10.1016/S0168-8278(18)31359-X
   Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Povsic M, Wong OY, Perry R, Bottomley J. A structured literature review of the epidemiology and disease burden of non-alcoholic steatohepatitis (NASH). Adv Ther. 2019;36(7):1574–1594. doi:10.1007/s12325-019-00960-3
   PubMed Web of Science ®Google Scholar
• McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148–1155. doi:10.1016/j.jhep.2014.11.034
   PubMed Web of Science ®Google Scholar
• Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–654.e641–649;quiz e639–640. doi:10.1016/j.cgh.2014.04.014
   Web of Science ®Google Scholar
• Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611–1625.e1612. doi:10.1053/j.gastro.2020.01.043
   PubMed Web of Science ®Google Scholar
• Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: facts and figures. JHEP Rep. 2019;1(6):468–479. doi:10.1016/j.jhepr.2019.10.008
   PubMedGoogle Scholar
• Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20(2):475–485. doi:10.3748/wjg.v20.i2.475
   PubMed Web of Science ®Google Scholar
• Anstee QM, Lawitz EJ, Alkhouri N, et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials. Hepatology. 2019;70(5):1521–1530. doi:10.1002/hep.30842
   PubMed Web of Science ®Google Scholar
• Ziecina R, Beasley S. Is liver biopsy a gold or an old standard in NAFL and NASH? International Biopharmaceutical Industry. 2019;2(4):20–23.
   Google Scholar
• Boursier J, Vergniol J, Guillet A, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol. 2016;65(3):570–578. doi:10.1016/j.jhep.2016.04.023
   PubMed Web of Science ®Google Scholar
• Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–1730. doi:10.1053/j.gastro.2019.01.042
   PubMed Web of Science ®Google Scholar
• Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51(3):828–835. doi:10.1002/hep.23425
   PubMed Web of Science ®Google Scholar
• Puri P, Sanyal AJ. Nonalcoholic fatty liver disease: definitions, risk factors, and workup. Clin Liver Dis. 2012;1(4):99–103. doi:10.1002/cld.81
   Google Scholar
• Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104–1112. doi:10.1016/j.cgh.2009.05.033
   PubMed Web of Science ®Google Scholar
• Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(1):156–163.e152. doi:10.1016/j.cgh.2018.04.043
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68(2):305–315. doi:10.1016/j.jhep.2017.11.013
   PubMed Web of Science ®Google Scholar
• Park SH, Kim SY, Suh CH, et al. What we need to know when performing and interpreting US elastography. Clin Mol Hepatol. 2016;22(3):406–414. doi:10.3350/cmh.2016.0106
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. doi:10.1002/hep.21178
   PubMed Web of Science ®Google Scholar
• McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740–751. doi:10.1038/ajg.2016.453
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver (EASL)., European Association for the Study of Diabetes (EASD). & European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59(6):1121–1140. doi:10.1007/s00125-016-3902-y
   PubMed Web of Science ®Google Scholar
• Alexander M, Loomis AK, Fairburn-Beech J, et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med. 2018;16(1):130. doi:10.1186/s12916-018-1103-x
   PubMedGoogle Scholar
• Nascimbeni F, Pais R, Bellentani S, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59(4):859–871. doi:10.1016/j.jhep.2013.05.044
   PubMed Web of Science ®Google Scholar
• Sheridan DA, Aithal G, Alazawi W, et al. Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Frontline Gastroenterol. 2017;8(4):252–259. doi:10.1136/flgastro-2017-100806
   PubMed Web of Science ®Google Scholar
• Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes – a means to understand. Curr Med Res Opin. 2008;24(11):3063–3072. doi:10.1185/03007990802457040
   PubMed Web of Science ®Google Scholar
• Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8):e010352. doi:10.1136/bmjopen-2015-010352
   PubMed Web of Science ®Google Scholar
• Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371–380. doi:10.2147/DMSO.S120101
   PubMed Web of Science ®Google Scholar
• Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF. Youden index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J. 2008;50(3):419–430. doi:10.1002/bimj.200710415
   PubMed Web of Science ®Google Scholar
• Caballería L, Pera G, Arteaga I, et al. High prevalence of liver fibrosis among European adults with unknown liver disease: a population-based study. Clin Gastroenterol Hepatol. 2018;16(7):1138–1145.e1135. doi:10.1016/j.cgh.2017.12.048
   PubMed Web of Science ®Google Scholar
• Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006–1019.
   PubMed Web of Science ®Google Scholar
• Selvaraj EA, Mózes FE, Jayaswal ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2021;75(4):770–785. doi:10.1016/j.jhep.2021.04.044
   PubMed Web of Science ®Google Scholar
• Davyduke T, Tandon P, Al-Karaghouli M, Abraldes JG, Ma MM. Impact of implementing a “FIB-4 first” strategy on a pathway for patients with NAFLD referred from primary care. Hepatol Commun. 2019;3(10):1322–1333. doi:10.1002/hep4.1411
   PubMed Web of Science ®Google Scholar
• Seeger JD, Nunes A, Loughlin AM. Using RWE research to extend clinical trials in diabetes: an example with implications for the future. Diabetes Obes Metab. 2020;22(Suppl3):35–44. doi:10.1111/dom.14021
   PubMedGoogle Scholar
• Camm AJ, Fox KAA. Strengths and weaknesses of ‘real-world’ studies involving non-vitamin K antagonist oral anticoagulants. Open Heart. 2018;5(1):e000788. doi:10.1136/openhrt-2018-000788
   PubMed Web of Science ®Google Scholar